Molecular mechanisms underlying chemopreventive activities of glycyrrhizic acid against UVB-radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis

Radiation Research

Volumn 176, Issue 2, 2011, Pages 177-186

  Cherng, Jaw Ming ^a   Tsai, Kuen Daw ^b,c   Yu, Yu Whay ^a   Lin, Jung Chung ^d  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; CYCLOOXYGENASE 2; DNA NUCLEOTIDYLEXOTRANSFERASE; GLYCYRRHIZIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; PROSTAGLANDIN E2; PROTEIN P21; PROTEIN P53; THYMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER INCIDENCE; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; EPIDERMIS; FEMALE; HAIRLESS MOUSE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RADIATION INDUCED NEOPLASM; ULTRAVIOLET B RADIATION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOOXYGENASE 2; DNA DAMAGE; EPIDERMIS; FEMALE; GLYCYRRHIZIC ACID; MICE; MICE, HAIRLESS; NEOPLASMS, RADIATION-INDUCED; NF-KAPPA B; NITRIC OXIDE; RADIATION-PROTECTIVE AGENTS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SUNBURN; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

MUS;

EID: 79961051534     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2510.1     Document Type: Article

References (40)

1. H. N. Ananthaswamy, Ultraviolet light as a carcinogen. In Comprehensive Toxicology (G. T. Bowden and S. M. Fischer, Eds.), pp. 255-279. Elsevier, New York, 1997.
2. B. K. Armstrong and A. Kricker, The epidemiology of UV induced skin cancer. J. Photochem. Photobiol. 63, 8-18 (2001). (Pubitemid 33040718)
3. V. O. Melnikova and H. N. Ananthaswamy, Cellular and molecular events leading to the development of skin cancer. Mutat. Res. 571, 91-106 (2005). (Pubitemid 40313435)
4. F. R. de Gruijl and P. D. Forbes, UV-induced skin cancer in a hairless mouse model. Bioessays 17, 651-660 (1995).
5. F. R. de Gruijl, H. J. Sterenborg, P. D. Forbes, R. E. Davies, C. Cole, G. Kelfkens, H. van Weelden, H. Slaper and J. C. van der Leun, Wavelength dependence of skin cancer induction by ultraviolet irradiation of albino hairless mice. Cancer Res. 53, 53-60 (1993). (Pubitemid 23019376)
6. F. R. de Gruijl, Photocarcinogenesis: UVA vs. UVB radiation. Skin Pharmacol. Appl. Skin Physiol. 15, 316-320 (2002).
7. D. E. Heck, A. M. Vetrano, T. M. Mariano and J. D. Laskin, UVB light stimulates production of reactive oxygen species: unexpected role for catalase. J. Biol. Chem. 278, 22432-22436 (2003). (Pubitemid 36830295)
8. R. Agarwal, Z. Y. Wang and H. Mukhtar, Inhibition of mouse skin tumor-initiating activity of DMBA by chronic oral feeding of glycyrrhizin in drinking water. Nutr. Cancer 15, 187-193 (1991).
9. M. Abe, F. Akbar, A. Hasebe, N. Horiike and M. Onji, Glycyrrhizin enhances interleukin-10 production by liver dendritic cells in mice with hepatitis. J. Gastroenterol. 38, 962-967 (2003). (Pubitemid 37455783)
10. D. Armanini, C. Fiore, M. J. Mattarello, J. Bielenberg and M. Palermo, History of the endocrine effects of licorice. Exp. Clin. Endocrinol. Diabetes 110, 257-261 (2002). (Pubitemid 35246741)
11. J. M. Cherng, H. J. Lin, M. S. Hung, Y. R. Lin, M. H. Chan and J. C. Lin, Inhibition of nuclear factor kappaB is associated with neuroprotective effects of glycyrrhizic acid on glutamate-induced excitotoxicity in primary neurons. Eur. J. Pharmacol. 547, 10-21 (2006).
12. C. Fiore, M. Salvi, M. Palermo, G. Sinigaglia, D. Armanini and A. Toninello, On the mechanism of mitochondrial permeability transition induction by glycyrrhetinic acid. Biochim. Biophys. Acta 1658, 195-201 (2004). (Pubitemid 39278483)
13. F. Kawakami, Y. Shimoyama and K. Ohtsuki, Characterization of complement C3 as a glycyrrhizin (GL)-binding protein and the phosphorylation of C3alpha by CK-2, which is potently inhibited by GL and glycyrrhetinic acid in vitro. J. Biochem. 133, 231-237 (2003). (Pubitemid 36362483)
14. Y. Fujisawa, M. Sakamoto, M. Matsushita, T. Fujita and K. Nishioka, Glycyrrhizin inhibits the lytic pathway of complement - possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis. Microbiol. Immunol. 44, 799-804 (2000).
15. N. Abe, T. Ebina and N. Ishida, Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol. Immunol. 26, 535-539 (1982). (Pubitemid 12068620)
16. M. Shinada, M. Azuma, H. Kawai, K. Sazaki, I. Yoshida, T. Yoshida, T. Suzutani and T. Sakuma, Enhancement of interferon-gamma production in glycyrrhizin-treated human peripheral lymphocytes in response to concanavalin A and to surface antigen of hepatitis B virus. Proc. Soc. Exp. Biol. Med. 181, 205-210 (1986). (Pubitemid 16166887)
17. H. T. Chan, C. Chan and J. W. Ho, Inhibition of glycyrrhizic acid on aflatoxin B1-induced cytotoxicity in hepatoma cells. Toxicology 188, 211-217 (2003). (Pubitemid 36588901)
18. E. Gumpricht, R. Dahl, M. W. Devereaux and R. J. Sokol, Licorice compounds glycyrrhizin and 18beta-glycyrrhetinic acid are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes. J. Biol. Chem. 280, 10556-10563 (2005). (Pubitemid 40395916)
19. Q. Z. Zheng and Y. J. Lou, Pathologic characteristics of immunologic injury in primary cultured rat hepatocytes and protective effect of glycyrrhizin in vitro. Acta Pharmacol. Sin. 24, 771-777 (2003).
20. J. Cinatl, Jr., M. Michaelis, G. Hoever, W. Preiser and H. W. Doerr, Development of antiviral therapy for severe acute respiratory syndrome. Antiviral Res. 66, 81-97 (2005). (Pubitemid 40720113)
21. J. C. Lin, Mechanism of action of glycyrrhizic acid in inhibition of Epstein-Barr virus replication in vitro. Antiviral Res. 59, 41-47 (2003).
22. J. C. Lin, J. M. Cherng, M. S. Hung, L. A. Baltina, L. Baltina and R. Kondratenko, Inhibitory effects of some derivatives of glycyrrhizic acid against Epstein-Barr virus infection: structureactivity relationships. Antiviral Res. 79, 6-11 (2008).
23. J. Cinatl, B. Morgenstern, G. Bauer, P. Chandra, H. Rabenau and H. W. Doerr, Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361, 2045-2046 (2003). (Pubitemid 36695048)
24. J. M. Crance, N. Scaramozzino, A. Jouan and D. Garin, Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res. 58, 73-79 (2003). (Pubitemid 36507224)
25. S. Briolant, D. Garin, N. Scaramozzino, A. Jouan and J. M. Crance, In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res. 61, 111-117 (2004). (Pubitemid 37506098)
26. J. M. Cherng, H. J. Lin, Y. H. Hsu, M. S. Hung and J. C. Lin, A quantitative bioassay for HIV-1 gene expression based on UV activation: effect of glycyrrhizic acid. Antiviral Res. 62, 27-36 (2004).
27. G. Hoever, L. Baltina, M. Michaelis, R. Kondratenko, G. A. Tolstikov, H. W. Doerr and J. Cinatl, Jr., Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus. J. Med. Chem. 48, 1256-1259 (2005). (Pubitemid 40270469)
28. T. G. van Rossum, A. G. Vulto, W. C. Hop, J. T. Brouwer, H. G. Niesters and S. W. Schalm, Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J. Gastroenterol. Hepatol. 14, 1093-1099 (1999).
29. P. Bean, The use of alternative medicine in the treatment of hepatitis C. Am. Clin. Lab. 21, 19-21 (2002).
30. J. T. Coon and E. Ernst, Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review. J. Hepatol. 40, 491-500 (2004). (Pubitemid 38230852)
31. H. Hibasami, H. Iwase, K. Yoshioka and H. Takahashi, Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells. Int. J. Mol. Med. 17, 215-219 (2006).
32. Y. P. Lu, Y. R. Lou, P. Yen, D. Mitchell, M. T. Huang and A. H. Conney, Time course for early adaptive responses to ultraviolet B light in the epidermis of SKH-1 mice. Cancer Res. 59, 4591-4602 (1999). (Pubitemid 29428964)
33. C. L. Chang, G. Mara, D. P. Chauhan, H. T. Ha, D. K. Chang, L. Ricciardiello, A. Randolph, J. M. Carethers and C. R. Boland, Oxidative stress inactivates the human DNA mismatch repair system. Am. J. Physiol. Cell Physiol. 283, C148-C154 (2002). (Pubitemid 34670558)
34. S. Rahman and S. Sultana, Glycyrrhizin exhibits potential chemopreventive activity on 12-O-tetradecanoyl phorbol-13-acetate-induced cutaneous oxidative stress and tumor promotion in Swiss albino mice. J. Enzyme Inhib. Med. Chem. 22, 363-369 (2007). (Pubitemid 47225729)
35. P. Mass, K. Hoffmann, T. Gambichler, P. Altmeyer and H. G. Mannherz, Premature keratinocyte death and expression of marker proteins of apoptosis in human skin after UVB exposure. Arch. Dermatol. Res. 295, 71-79 (2003). (Pubitemid 36791726)
36. A. Ouhtit, A. Gorny, H. K. Muller, L. L. Hill, L. Owen-Schaub and H. N. Ananthaswamy, Loss of Fas-ligand expression in mouse keratinocytes during UV carcinogenesis. Am. J. Pathol. 157, 1975-1981 (2000).
37. S. R. Pinnell, Cutaneous photodamage, oxidative stress, and topical antioxidant protection. J. Am. Acad. Dermatol. 48, 1-19 (2003). (Pubitemid 36091527)
38. N. Ahmad, L. C. Chen, M. A. Gordon, J. D. Laskin and D. L. Laskin, Regulation of cyclooxygenase-2 by nitric oxide in activated hepatic macrophages during acute endotoxemia. J. Leukoc. Biol. 71, 1005-1011 (2002).
39. M. Kojima, T. Morisaki, K. Izuhara, A. Uchiyama, Y. Matsunari, M. Katano and M. Tanaka, Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation. Oncogene 19, 1225-1231 (2000). (Pubitemid 30157553)
40. B. L. Diffey, Solar ultraviolet radiation effects on biological systems. Phys. Med. Biol. 36, 299-328 (1991).